Novo Nordisk - HealthQuill

US-based biotechnology company Viking Therapeutics Inc., reported “positive” results from its early-stage weight-loss oral drug and the pill showed mild to moderate side effects.

Viking Therapeutics’ weight-loss drug shows ‘positive’ results in early trials

US-based biotechnology company Viking Therapeutics Inc., reported “positive” results from its early-stage weight-loss oral drug and the pill showed mild to moderate side.

by HealthQuill
March 27, 2024
0 Comments

Novo Nordisk, one of the world’s most valuable companies, will acquire Germany-based Cardior Pharmaceuticals, a firm that specialises in heart diseases, for up to 1.03 billion euros ($1.1 billion).

Drugs Health Pharma

Novo to buy Cardior for $1.1b to expand cardiovascular segment

HQ Team March 25, 2024: Novo Nordisk, one of the world’s most valuable companies, will acquire Germany-based Cardior Pharmaceuticals, a firm that specialises.

by HealthQuill
March 25, 2024
0 Comments

Danish drugmaker Novo Nordisk’s oral medicine, amycretin, for obesity can cause up to 13% weight loss, the company announced.

Drugs Health Pharma

Novo Nordisk unveils new drug to fight obesity, says 13% effective

HQ Team March 11, 2024: Danish drugmaker Novo Nordisk’s oral medicine, amycretin, for obesity can cause up to 13% weight loss, the company.

by HealthQuill
March 11, 2024
0 Comments

Novo Nordisk’s diabetes drug Ozempic delayed the progression of kidney disease and cardiovascular and kidney death in 24% of people involved in trials, the company announced.

Drugs Health Pharma

Novo Nordisk says Ozempic reduces kidney disease progression

HQ Team March 6, 2024: Novo Nordisk’s diabetes drug Ozempic delayed the progression of kidney disease and cardiovascular and kidney deaths in 24%.

by HealthQuill
March 6, 2024
0 Comments

Eli Lilly, a US company that forecasts revenue of up to $33.9 billion, plans to build a $2.5 billion plant in Germany to make devices for treating diabetes and obesity.

Drugs Health Pharma

Novo Nordisk buys 3 Catalent sites for $11bn to meet rising demand for Wegovy

HQ Team February 5, 2024: Novo Nordisk will acquire three manufacturing sites in an $11bn deal to expand its production of weightless drugs.

by HealthQuill
February 5, 2024
0 Comments

Denmark’s Novo Nordisk declared its late-stage experimental once-weekly diabetes drug IcoSema achieved its primary endpoint of proving “non-inferiority” in lowering blood sugar levels.

Drugs Health Pharma

Novo Nordisk diabetes drug meets trial goals against insulin glargine

HQ Team January 9, 2023: Denmark’s Novo Nordisk declared its late-stage experimental once-weekly diabetes drug IcoSema achieved its primary endpoint of proving “non-inferiority” in.

by HealthQuill
January 9, 2024
1 Comment

The FDA has seized “thousands of units” of counterfeit weight-loss injection Ozempic which have no information about the drug’s identity, quality or safety.

Drugs Health Pharma

FDA starts crackdown against fake Ozempic weight-loss drug

HQ Team December 22, 2023: The FDA has seized “thousands of units” of counterfeit weight-loss injection Ozempic which have no information about the.

by HealthQuill
December 22, 2023
0 Comments

Semaglutide based weightloss drugs tied to increased suicide risk in a new study

Drugs Health Pharma

EMA expands probe into suicidal thoughts linked to weight loss drugs

HQ Team December 2, 2023: The European Medicines Agency (EMA) is intensifying its investigation into the potential link between certain GLP-1 receptor agonist.

by HealthQuill
December 2, 2023
2 Comments

Pfizer Inc., has discontinued its clinical trials of the twice-daily oral weight-loss drug, danuglipron, after more than 50% of the patients opted out due to adverse effects of the medicine.

Drugs Health Pharma

Pfizer Inc., stops twice-daily oral obesity drug trial at mid-stage

HQ Team December 2, 2023: Pfizer Inc., has discontinued its clinical trials of the twice-daily oral weight-loss drug, danuglipron, after more than 50%.